Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$5.78 USD

5.78
34,571

-0.05 (-0.86%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $5.88 +0.10 (1.73%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Weekly Biotech Update After WHO Declares Coronavirus a Pandemic

Several pharma/companies are working to develop a treatment for novel coronavirus as WHO declares Covid-19 a pandemic.

Kinjel Shah headshot

3 Small Biotechs Provide Coronavirus Drug Development Updates

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

Why Kamada (KMDA) Could Beat Earnings Estimates Again

Kamada (KMDA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Kamada (KMDA) Beats Q3 Earnings and Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 66.67% and 14.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) to Report Q3 Results: Wall Street Expects Earnings Growth

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 6.67% and 4.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services

Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services

Moumita C. Chattopadhyay headshot

Look Beyond Earnings: 4 Stocks With Increasing Cash Flows

Cash is an indispensable factor for any company. It gives strength and vitality to a company and is the key to its existence, development and success.

Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX

Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX

Tap These 6 Stocks That Flaunt Impressive Net Profit Margin

Let's consider six stocks with a remarkable net profit margin to build a successful portfolio.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for July 16th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Kamada (KMDA) Tops Q1 Earnings and Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 160.00% and 17.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

Kamada (KMDA) Stock Moves -1.05%: What You Should Know

Kamada (KMDA) closed the most recent trading day at $5.67, moving -1.05% from the previous trading session.

Kamada (KMDA) Gains As Market Dips: What You Should Know

Kamada (KMDA) closed the most recent trading day at $5.83, moving +1.57% from the previous trading session.

Kamada (KMDA) Gains As Market Dips: What You Should Know

Kamada (KMDA) closed at $6.13 in the latest trading session, marking a +0.02% move from the prior day.

Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?

Is (KMDA) Outperforming Other Medical Stocks This Year?

Kamada to Begin Phase III Study for Inhaled AAT Product in 2H

Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.

Moumita Chattopadhyay headshot

5 Stocks With Increasing Cash Flows to Scoop Up Big Gains

Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

Acorda to Gain From Inbrija Sales and Neurological Pipeline

Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

Kamada (KMDA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Kamada (KMDA) closed at $5.95, marking a -1.16% move from the previous day.

Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin

Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.